Multivariate analysis established FIGO stage III-IV, HE4 > 140 pmol/L, and a high-risk LogitScore as independent risk factors for shorter RFS.<h4>Conclusion</h4>The combination of pretreatment serum HE4, a composite LogitScore, and FIGO stage represents a promising indicator set for predicting cervical cancer recurrence in this exploratory, internally validated analysis. The gene discussed is WFDC2; the disease is cervical cancer.